AIMDHIGH SIGNALRISK10-K

AIMD has undergone a dramatic strategic pivot from diversified healthcare to AI-based "smelltech" while experiencing severe cash deterioration that raises immediate liquidity concerns.

The company has fundamentally repositioned itself around an unproven AI olfaction technology platform called "AI Nose" while abandoning its previous focus on point-of-care testing and interferon therapeutics. This represents a complete business model transformation during a period of financial distress, significantly increasing execution risk and uncertainty about the viability of the new strategic direction.

Comparing 2026-03-30 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

The financial picture is deeply concerning, with cash and equivalents plummeting to just $417K from $3.9M, representing a severe liquidity crisis. While current liabilities decreased proportionally, operating cash flow remains substantially negative at -$4.6M despite modest improvement. The combination of deteriorating cash position, continued operating losses, and a complete strategic pivot creates a precarious situation that may challenge the company's ability to fund operations and execute its new AI-focused strategy.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-89.3%
$3.9M→$417K

Cash declined 89.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-73.7%
$4.3M→$1.1M

Current assets declined 73.7% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
-72.7%
$4.0M→$1.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
+62%
$21K→$35K

Capital expenditure jumped 62% — major investment cycle underway; assess returns on deployment.

Accounts Receivable
Balance Sheet
-60.7%
56→22

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
-51.3%
$15.5M→$7.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Assets
Balance Sheet
-27.6%
$28.8M→$20.9M

Total assets contracted 27.6% — asset sales, write-downs, or balance sheet optimization underway.

Operating Cash Flow
Cash Flow
+20.5%
-$5.8M→-$4.6M

Operating cash flow grew 20.5% — strong conversion of earnings to cash, healthy business fundamentals.

SG&A Expense
P&L
+17.6%
$5.4M→$6.3M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-07
ADDED
As of March 30, 2026, there were issued and outstanding 7,266,011 shares of the registrant s common stock, par value $ 0.01 , which is the only class of common or voting stock of the registrant.
(the Company ), incorporated in the State of Texas in 1984, is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics.
Our primary strategic focus is the commercialization of our proprietary scent digitization platform, AI Nose, while we also continue to develop therapeutic assets based on our low-dose oral interferon program, VELDONA .
Our core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which we refer to as a smell language model ( SLM ), to digitize scent and volatile organic compound ( VOC ) signals into Smell ID, a machine-readable data format.
AI Nose is initially developed in healthcare-related settings, including point-of-care testing ( POCT ).
These early healthcare applications shaped the platform s sensor architecture, data models, and system calibration.
Building on this foundation, we are expanding the application of AI Nose into industrial environments, where we believe real-time environmental sensing, anomaly detection, and operational monitoring are important.
Current and planned use cases include industrial applications across semiconductor manufacturing, robotics, and smart manufacturing settings.
We believe the underlying scent digitization architecture of AI Nose is adaptable across a range of industrial and non-industrial verticals, and we continue to evaluate additional application opportunities based on partner engagement and deployment experience.
3 We are advancing the AI Nose platform through partner-led deployments, with a strategy focused on platform scalability, data-driven performance improvement, and integration into existing industrial ecosystems.
REMOVED
As of June 30, 2024, the aggregate market value of the shares of common stock outstanding, other than shares held by persons who may be deemed affiliates of the Registrant, computed by reference to the closing price of $ 0.8136 for the Registrant s common stock on June 30, 2024, as reported on Nasdaq Capital Market, was approximately $ 3,350,118 .
(the Company ), incorporated in the State of Texas in 1984, is a diversified healthcare company focused on the development of novel point-of-care testing (the POCT ), therapeutics based on very low-dose interferon alpha (the VELDONA ), and synthetic RNA-driven preventative medicine.
Our product pipeline includes commercial-stage VELDONA Pet supplements, clinical-stage VELDONA human therapeutics and telehealth-friendly POCTs powered by the AI Nose technology platform.
Our vision for AI Nose is to digitize smell, extend application beyond healthcare, and ultimately become AI s nose.
We have historically involved in the research and development of therapeutics based on VELDONA.
Building on our research and development on VELDONA since inception, we are focused on commercializing a suite of VELDONA-based product candidates.
Our priority pipeline includes drug candidates for treating oral warts for human immunodeficiency virus (HIV) seropositive patients, Sj gren s syndrome, and feline chronic gingivostomatitis (FCGS), a cat oral infection.
In 2021 and 2022, we acquired certain types of intellectual property from a controlling shareholder, Ainos Inc., a Cayman Island corporation ( Ainos KY ), to expand product portfolio into POCTs aimed to provide connected, rapid, and convenient testing for a broad range of health conditions.
Pivoting from the sales of COVID-19 POCT, we aim to commercialize POCTs that detect volatile organic compounds (the VOC ) emitted by the body, powered by our AI Nose technology platform.
In 2024, we licensed certain patents and patent applications from Taiwan Carbon Nano Technology Corporation ( TCNT ), a controlling shareholder, to further expand our intellectual properties on our VOC and POCT technologies.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →